Previous Article | Next Article 
Infection and Immunity, December 1999, p. 6314-6320, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cytokine Profiles of AIDS Patients Are Similar to Those of Mice
with Disseminated Cryptococcus neoformans
Infection
Olivier
Lortholary,1
Luce
Improvisi,1
Naima
Rayhane,2
Francoise
Gray,3
Catherine
Fitting,2
Jean Marc
Cavaillon,2 and
Francoise
Dromer1,*
Unité de
Mycologie1 and Unité
d'Immuno-Allergie,2 Institut Pasteur, 75724 Paris Cedex 15, and Service d'Anatomie et de Cytologie
Pathologiques, Hôpital Raymond Poincaré, 92380 Garches,3 France
Received 28 June 1999/Returned for modification 6 August
1999/Accepted 1 September 1999
 |
ABSTRACT |
Cryptococcosis is an hematogenously disseminated
meningoencephalitis during which the relationship between the disease
severity and the immune response remains unclear. We thus analyzed, by enzyme-linked immunosorbent assay, proinflammatory (tumor necrosis factor alpha [TNF-
] and interleukin-6 [IL-6]) and
anti-inflammatory (IL-10) cytokine levels in plasma at the time of
diagnosis in 51 AIDS patients with culture-proven cryptococcosis.
We used a murine model to determine the correlation between cytokine
levels and fungal burden in blood and tissues and the kinetics of the immune response and of the formation of cerebral lesions. In AIDS patients, plasma TNF-
and IL-10, but not IL-6, levels were
significantly higher in the case of fungemia or disseminated
infection than in their absence, whereas the presence of meningitis had
no influence on these levels. In mice, none of these cytokines were
detected within the first day after inoculation. Later on,
TNF-
and IL-10, but not IL-6, levels in plasma correlated
significantly with the fungal burden in the blood and spleen but not
the brain. In the brain, cytokine levels were low compared to those in
other compartments, and tissue lesions and a degree of infection
similar to those observed in humans were seen, further suggesting the
relevance of this experimental model. Thus, AIDS patients with
cryptococcosis produce an immune response that reflects the
dissemination but not the meningeal involvement. This murine model of
disseminated cryptococcosis can be used to investigate the
pathophysiology of cryptococcosis and new therapeutic approaches.
 |
INTRODUCTION |
Cryptococcus neoformans
is an encapsulated yeast responsible for severe meningitis and
disseminated infections, including fungemia, mostly in patients with
AIDS (14). In this group, 10 to 25% of patients die during
initial antifungal therapy (32). Thus, improving the
prognosis of this life-threatening opportunistic mycosis may require
new therapeutic approaches such as immunointervention. However,
immunotherapeutic trials cannot be designed without a comprehensive
understanding of the immune response to C. neoformans in
humans. Although there is a multitude of nonspecific effector cells
capable of killing or inhibiting C. neoformans,
cell-mediated immunity is a confirmed key host defense mechanism
against C. neoformans (6, 35). Studies with mice
have documented the roles of several cytokines, such as tumor necrosis
factor alpha (TNF-
), gamma interferon (IFN-
), and interleukin 12 (IL-12), in the host defense against C. neoformans through
their exogenous administration (22, 23, 25), the
administration of specific anticytokine antibodies (1, 18,
21) or the use of cytokine-deficient mice generated by gene
disruption (11, 36, 41). In addition, several recent in
vitro studies focused on the production of various cytokines by human
neutrophils and mononuclear cells incubated with C. neoformans. However, the use of different experimental conditions
prevents any definitive conclusion on the role of these cytokines and
their relationship during cryptococcosis (7, 28, 37, 38).
Nevertheless, some of these studies clearly demonstrated a
dose-dependent induction of cytokine secretion by human cells after
stimulation with the cryptococcal glucuronoxylomannan (GXM) or with
intact cells (13, 37, 38). Whether these experimental data
will reflect the immune activation induced by C. neoformans in humans remains to be determined.
Thus, the main purpose of the present study was to investigate the
cytokine response to C. neoformans infection in AIDS
patients and to assess whether there was a relationship between
cytokine profiles in plasma and the initial severity of the disease as evaluated by the presence of fungemia, meningeal involvement, or
dissemination. Because precise quantification of tissue infection in
humans is precluded, a murine model was needed to assess the influence
of fungal load on cytokine responses in the target compartments. Furthermore, the model was also mandatory to evaluate the kinetics of
the immune response to C. neoformans infection. Since the
human disease is usually a disseminated meningoencephalitis, we chose a
route of inoculation that leads to progressive disseminated infection
in outbred mice and assessed the clinical relevance of this model. We
did so by comparing fungal loads and histopathologies of brain tissues
obtained from a rapidly fatal case of AIDS-associated disseminated
cryptococcosis and from mice sacrificed at various times after inoculation.
(This work was presented in part at the 38th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September 1998 [30a].)
 |
MATERIALS AND METHODS |
Human study.
The human study was done in accordance with a
prospective protocol approved by the Ethical Committee of the Groupe
Hospitalier Necker Enfants-Malades, Paris, France (DGS 970089, French
Ministry of Health). Patients were enrolled anonymously, and all
samples were assayed blindly. Plasma samples obtained within 2 days
after the diagnosis of cryptococcosis from 51 AIDS patients with
culture-confirmed cryptococcosis were studied. All of the patients had
at least a culture of blood, cerebrospinal fluid, and urine before
receiving antifungal therapy, and their median CD4 cell count was
28/mm3. Patients were considered to have disseminated
infection if C. neoformans was cultured from at least two
sites. Plasma samples were kept frozen at
80°C until assayed. Upon
thawing, the samples were used for the measurement of TNF-
and IL-10
within the same day and then aliquoted and stored at
80°C prior to
the measurement of IL-6. TNF-
, IL-6, and IL-10 concentrations were
determined by an enzyme-linked immunosorbent assay (R & D Systems,
Abingdon, United Kingdom) by comparison with standard curves. All
samples were tested individually. According to the manufacturer, the
minimum detectable levels of TNF-
, IL-6, and IL-10 in plasma were
4.4, 0.7, and 2.0 pg/ml, respectively.
Experimental studies. (i) Infecting organism.
The isolate of
C. neoformans (NIH 52D) was subcultured in yeast nitrogen
base broth supplemented with 2% glucose (Difco Laboratories, Detroit,
Mich.) for 18 h on a rotary shaker at 30°C. The inoculum was
prepared in sterile saline, as reported before (15), and 200 µl was injected into the lateral tail vein of each mouse.
(ii) Experimental infections.
Outbred male OF1 mice (Ico:
OF1 [I.O.P.S. Caw]; mean body weight, 22 g) (Iffa Credo,
l'Arbresle, France) were used. Five to eight mice per cage were housed
in our animal facilities and received food and water ad libitum. Animal
experimentation guidelines were respected in these studies.
The cytokine responses and the fungal burdens in blood and target
organs in groups of five mice were studied as a function of the
inoculum size (2 × 104, 2 × 105, or
2 × 106 per mouse) or the time of sacrifice (day 1, 3, 6, 8 or 10). The experiments were repeated twice or thrice (CFU
counts and cytokine production on days 1 and 6 to 8). In this case,
results from one representative experiment are shown.
(iii) Blood and tissue cultures.
From animals that had been
euthanized, approximately 1 ml of blood was obtained by cardiac
puncture. The plasma samples were individually aliquoted and frozen at
80°C. Fungemia was assessed by culturing buffy coats as previously
described (31). The lung, spleen, and brain were aseptically
removed, weighed, and ground in 1,000 µl of sterile
phosphate-buffered saline containing 3% bovine serum albumin (Miles
Laboratories, Spokane, Wash.). Tenfold dilutions of the homogenates
were plated (100 µl) in duplicate on Sabouraud-chloramphenicol
agar-coated petri dishes and incubated at 28°C for 48 h. Results
are expressed as log10 CFU per gram of organ. When
appropriate, the remaining homogenates were then centrifuged (14,000 rpm, 10 min), and the supernatants were immediately frozen at
80°C
for subsequent determination of cytokine levels (see below).
(iv) Murine cytokine immunoassays.
Cytokine concentrations
in plasma and supernatants of ground organs were assessed by
enzyme-linked immunosorbent assay (R & D Systems) and determined by
comparison with standard curves. Preliminary results showed that the
curves obtained with the internal standard diluted in the provided
buffer and with phosphate-buffered saline-3% bovine serum albumin
were superposable (data not shown). All samples were tested
individually. Cytokine concentrations in organs were expressed in
picograms per gram by using the following formula: concentration in the
supernatant in picograms per milliliter/organ weight in grams.
According to the manufacturer, the minimum detectable levels of
TNF-
, IL-6, IFN-
, and IL-10 in plasma were 5, 3, 2, and 4 pg/ml,
respectively. The corresponding lowest possible detection thresholds,
expressed in picograms per gram of organ for the mice used in these
experiments, were calculated based on the heaviest organs excised and
were, respectively, 10, 6, 4, and 8 pg/g. Cytokine concentrations in
all samples from naive mice were undetectable.
(v) Comparative histopathological study.
The brain recovered
during the autopsy of an AIDS patient who died 2 days after the
diagnosis of disseminated cryptococcosis was studied, as were those
from mice inoculated with this patient's strain or with NIH 52D
(2 × 105 cryptococci/mouse, as described above) and
sacrificed (groups of three mice) at days 1, 3, 8, and 15 postinoculation. The experiment using NIH 52D was repeated twice. After
removal, all of the specimens were fixed in 10% formalin solution,
paraffin embedded, and sectioned coronally at 4-µm thickness.
Sections were stained with hematoxylin-eosin, periodic acid-Schiff
stain, blue-alcian, and Gomori-Grocott. All of the slides were analyzed
blindly by one of the authors (F.G.). Upon removal, a sample from the
brain of the patient and a sample from each mouse were immediately
processed for CFU enumeration as described above.
(vi) Statistical methods.
Statistical analyses were
performed with Statview 4.5 (Abacus Concepts, Inc., Berkeley, Calif.).
CFU and cytokine levels were compared by using the Mann-Whitney U test
or Kruskal-Wallis test, depending on the number of groups. The Spearman
test was used to establish correlations between cytokine levels and CFU
or between levels of two cytokines after pooling results (for mice used
in at least three independent experiments starting on day 6 and
sacrificed 6 to 10 days after infection with 2 × 106
cryptococci per mouse, n = 15 to 27). A correlation was
taken into account as of rs
0.80.
Significance was defined as P
0.05.
 |
RESULTS |
Histopathological study.
The microscopic examination of the
patient's brain showed occasional inflammatory cells and numerous
cryptococci in the leptomeninges, extending into the brain parenchyma
along the perivascular spaces, where they formed cysts. In mice,
lesions appeared 3 days after inoculation, but significant changes were
not obvious until day 8 after infection with both the patient's strain
and NIH 52D. At that time, lesions were similar to those observed in
the patient's brain (Fig. 1), and
enumeration of CFU per gram of organ found a similar degree of
infection (the log10 CFU per gram of brain was 6.5 for the
patient, 7.4 ± 0.2 for the mice inoculated with the corresponding
strain, and 6.8 ± 0.3 for mice inoculated with NIH 52D). As
cerebral lesions and fungal loads in the mouse brains at 8 days after
inoculation were similar to those observed in the AIDS patient who died
shortly after the diagnosis of cryptococcosis, we considered day 8 to
be relevant for the study of the immune response in mice.

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 1.
Comparative histopathological analysis of brain sections
of mice sacrificed 8 days after inoculation with 2 × 105 C. neoformans organisms/mouse (panel 1) and
of an AIDS patient who died of disseminated cryptococcosis (panel 2).
Magnification, ×1,000. The strain inoculated into mice was cultured
from the patient. LM, leptomeninges; E, edema; C, cyst.
|
|
Cytokine patterns in the plasma of AIDS patients with
cryptococcosis.
Since quantitative cultures for the detection of
C. neoformans in blood and tissues are not routinely
performed for humans, results are interpreted here in the light of
positive or negative cultures. Median plasma TNF-
and IL-10, but not
IL-6, levels were significantly higher in AIDS patients with
cryptococcemia than in patients with negative blood culture and were
significantly higher in patients with disseminated cryptococcosis than
in patients with a single site infected (Fig.
2). Levels of these three cytokines in
plasma were similar whether the patients had culture-confirmed meningitis or no meningeal involvement.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Distribution of TNF- , IL-10, and IL-6 baseline levels
in plasma of AIDS patients with cryptococcosis according to the
presence ( ) or absence ( ) of fungemia (A) (n = 27
and 24, respectively), dissemination (B) (n = 36 and
15, respectively), and culture-confirmed meningitis (C) (n = 44 and 7, respectively). Lines through boxes show medians, with
other quartiles at either end. Bars show the 10th and 90th centiles.
Dots represent individual values above the 90th centile or below the
10th centile. Significant differences between patients with or without
fungemia and with or without dissemination were found for TNF-
(P = 0.001 and P = 0.01, respectively)
and IL-10 (P = 0.002 and P = 0.04,
respectively) in plasma.
|
|
Course of infection in OF1 mice.
As previously determined with
this model, survival and early CFU counts in blood and tissues depended
on the inoculum size (31). At the early phase of infection
(day 6 or earlier), for a given inoculum the groups were very
homogeneous regarding fungal burdens in all organs and in blood (
10%
variation). Afterwards, a plateau (median log10 CFU, 7.01;
range, 6.47 to 7.71) was reached in the brain whatever the size of the
inoculum, whereas the fungal burden in the other compartments (spleen,
lungs, and blood) varied more from mouse to mouse (31). A
representative course of infection in mice inoculated with 2 × 106/mouse is shown in Fig. 3.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Fungal burden and TNF- , IL-6, and IL-10 levels in
plasma and in spleen and brain homogenates in OF1 mice. Mice were
sacrificed on days 3 ( ), 6 ( ), 8 ( ), and 10 ( ) after
inoculation with 2 × 106 C. neoformans
organisms. Results are expressed as means ± standard errors of
the means (n = 5 in each group).
|
|
Impact of fungal load on cytokine expression in mice.
On day
1, despite fungemia, none of the mice (except one infected with the
highest inoculum) had detectable plasma TNF-
(15 pg/ml) and IL-6 (40 pg/ml), and none had detectable IL-10 levels. It was verified in other
experiments that no TNF-
or IL-6 was produced even earlier (1.5 and
5 h) after intravenous inoculation (data not shown). Plasma
TNF-
and IL-10 levels increased significantly in parallel during the
course of the infection (P < 0.004), while those of
IL-6 did not (Fig. 3). The influence of fungal load was also seen on
day 8, when plasma TNF-
levels differed significantly as a function
of the inoculum size (P < 0.005) but those of IL-6 did
not (Fig. 4). Significant correlations
were established between plasma TNF-
and IL-10 levels
(rs = 0.947).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
TNF- and IL-6 levels in plasma and in spleen, lung,
and brain homogenates 8 days after inoculation of OF1 mice with 2 × 104 ( ), 2 × 105 ( ), or 2 × 106 ( ) C. neoformans organisms/mouse. Results
are expressed as means ± standard errors of the means
(n = 5 in each group).
|
|
Significant correlations were also established between plasma TNF-
levels and spleen CFU (rs = 0.890) and
fungemia (rs = 0.853), but not brain CFU
(rs = 0.608) (Fig.
5), and similarly between plasma IL-10
levels and spleen CFU (rs = 0.860) and
fungemia (rs = 0.819), but not brain CFU
(rs = 0.574).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
Correlations between TNF- in plasma plotted versus
fungal burden in buffy coat (A) or brain (B) in OF1 mice. Mice were
sacrificed between days 6 and 10 after inoculation with 2 × 106 C. neoformans organisms. Each dot represents
an individual sample (n = 27).
|
|
Locally in infected tissues, the size of the inoculum had no
significant influence on TNF-
and IL-6 concentrations in the spleens
and lungs on day 1 (data not shown) and day 8 (Fig. 4). Spleen TNF-
levels varied significantly over time (Fig. 3) (P < 0.001), while IL-6 and IL-10 concentrations remained stable. In
brains, despite the local infection and regardless of the inoculum tested, no TNF-
and IL-6 were detected on day 1. Thereafter, brain
TNF-
levels increased significantly over time (P < 0.02), while IL-6 concentrations peaked on day 6 after infection
and decreased thereafter (P < 0.03), and IL-10 levels
in most of samples remained below the detection threshold (Fig. 3).
Overall, no correlations were found between local cytokine levels and
the concomitant fungal burdens in the organs studied.
As IFN-
is known to enhance the in vitro TNF-
production induced
by C. neoformans (28), we wondered if the lack of
TNF-
production early after inoculation was related to the absence of IFN-
production. Plasma IFN-
was detected as early as day 1 (median, 8 pg/ml; range, 5 to 12 pg/ml) and increased over time. Significant correlations were established between plasma TNF-
and
IFN-
(rs = 0.871). Spleen IFN-
levels
varied significantly over time (Fig. 3) (P < 0.001),
while brain IFN-
concentrations peaked on day 6 after infection and
decreased thereafter (P < 0.03) (Fig.
6).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 6.
IFN- levels in plasma and in spleen and brain
homogenates of OF1 mice. Mice were sacrificed on days 3 ( ), 6 ( ),
8 ( ), and 10 ( ) after inoculation with 2 × 106
C. neoformans organisms. Results are expressed as means ± standard errors of the means (n = 5 in each
group).
|
|
 |
DISCUSSION |
We demonstrated in the present study the clinical relevance of an
experimental model of disseminated cryptococcosis obtained after
intravenous inoculation in outbred mice. Indeed, we were able to show
that histopathological lesions and fungal loads in the brain were
similar late in the course of experimental infection to what was
observed in an AIDS patient who died shortly after the diagnosis of
disseminated cryptococcosis and to the brain lesions reported by Lee et
al. for an autopsy series of 13 human immunodeficiency virus-infected
patients with cryptococcal meningitis (27). We also observed
similar cytokine profiles in immunocompetent mice and in AIDS patients
and an influence of fungal burden on the expression of some cytokines
in both settings. For AIDS patients, we found evidence that fungemia
and dissemination of C. neoformans infection influenced the
production of TNF-
, as measured in the blood compartment. To better
study the correlation between the cytokine response and the fungal
load, we used quantitative cultures of yeasts in the blood and in
target tissues of infected mice. We demonstrated a clear correlation
between plasma TNF-
levels and fungal loads in blood and spleen,
independently of the duration of infection in mice. Overall, our data
show that the proinflammatory cytokine TNF-
is a marker of fungal
load during disseminated cryptococcosis in humans and mice. Several in
vitro studies have already shown that capsule components or
cryptococcal cells themselves are able to stimulate TNF-
production
by various types of cells (8, 10, 13, 20, 28, 37, 39), and
some of these papers have pointed out a dose-dependent secretion of
TNF-
by cells that had been stimulated with GXM (37) or
intact cryptococci (13).
Our failure to demonstrate any correlation between plasma IL-6 levels
and fungal loads in both mice and humans differs from the data reported
for bacterial sepsis, where higher plasma IL-6 levels are found for
nonsurviving individuals (17, 34). The lack of correlation
between plasma IL-6 and TNF-
levels, however, is in agreement with
the TNF-
-independent IL-6 production previously demonstrated during
experimental bacterial sepsis (2, 17) and for human
monocytes stimulated with C. neoformans components (12). Very little is known about the parameters influencing IL-6 synthesis after exposure to C. neoformans or its
components. However, it was found that complement was required to
trigger IL-6 secretion by human monocytes (12) and to
transcribe IL-6 mRNA in rat alveolar macrophages (30).
Another group has demonstrated that the magnitude of IL-6 release by
human neutrophils reflected capsule thickness (37). Thus,
the differences that we observed between plasma IL-6 and TNF-
profiles and fungal loads and their independent evolution in the host
suggest the systematic study of the various parameters in vitro, as
done by Retini et al. (37).
Another fact to be noted is the delayed and low expression of
proinflammatory cytokines in the plasma of infected animals. Indeed,
although fungemia was documented within the first 24 h, no
proinflammatory cytokine response was observed in the plasma until day
3 after inoculation. These results contrast markedly with those
observed after intravenous injection of bacterial lipopolysaccharide (LPS), when TNF-
and IL-6 peaked at high levels 1.5 h after
inoculation and then declined (2, 9), but they agree with in
vitro data showing that C. neoformans induction of TNF-
synthesis by human monocytes occurred late (
18 h) compared to
LPS-induced production (
3 h) (28, 39).
We wondered whether the lack of an early inflammatory response in the
plasma after C. neoformans inoculation reflected imbalances in the cytokine network which justifies our kinetic study of the expression of IFN-
and IL-10. The first explanation would be a
GXM-induced down regulation of TNF-
secretion, like that reported for human monocytes (39). This possibility seems unlikely,
as the cryptococcal antigen concentration is low early after
inoculation (4). Second, IL-10 could have down regulated
TNF-
in vivo, as observed in vitro with human monocytes or
peripheral blood mononuclear cells in response to LPS or C. neoformans (29, 38, 40). However, we were unable to
detect IL-10 in the plasma early during the course of the experimental
infection, and its concentrations in plasma became correlated
significantly with TNF-
levels later on. In addition, the higher
IL-10 levels found in AIDS patients with cryptococcemia compared to
those with negative blood cultures and the correlation between the
plasma IL-10 level and fungal load found in mice are in agreement with
the dose-dependent induction of IL-10 secretion by human monocytes
after stimulation with GXM (38). Since IFN-
is known to
enhance the in vitro TNF-
production by C. neoformans-activated macrophages (28), we verified in the mouse model that the delayed secretion of TNF-
was not due to an
absence of IFN-
stimulation.
Thus, our results with mice and humans disagree with the classical
concept of Th1-Th2 balance (33), since plasma TNF-
, IFN-
, and IL-10 concentrations rose in concert. Interestingly, when
measuring cytokines produced in vitro by pulmonary T cells from mice
infected intratracheally with C. neoformans, Huffnagle observed that both Th1- and Th2-type cytokines were secreted
(19). Furthermore, using the same pulmonary model of
cryptococcosis, Kawakami et al. found that IL-12 administration
increased pulmonary IFN-
and IL-10 levels (24).
The lack of early production of proinflammatory cytokines could prevent
activation of defense mechanisms against C. neoformans and
result in progressive disease. Indeed, TNF-
is necessary for the
induction of the protective immune response against C. neoformans, as shown by the exogenous administration of TNF-
(23) or anti-TNF-
serum (21). Using the same
model of disseminated infection after intravenous inoculation of strain
NIH 52D, we were also able to show that mice deficient in both TNF-
and lymphotoxin-
genes were more susceptible to disseminated
C. neoformans infection than their wild counterparts
(36), thus confirming the importance of TNF-
and
lymphotoxin-
in the cytokine network involved in the host defense
against C. neoformans.
Keeping in mind that the brain is the target organ during
cryptococcosis (14), one of the most important observations
is the compartmentalization of cytokine production, as shown by
differences between the brain and the other compartments. This was
evidenced by identical cytokine levels in the plasma samples from AIDS
patients with meningeal involvement and from those without such
involvement and by the absence of a correlation between cytokine levels
in plasma and the severity of cerebral infection in mice. In addition, despite the use of various inoculum sizes and study up to premortem stages with CFU counts as high as 7 log10 CFU/g of brain,
all brain cytokine levels except those of IFN-
remained low compared to those measured in the other compartments. Interestingly, after inoculating C. neoformans intracisternally, Blasi et al.
observed IL-6, but not TNF-
, gene expression in the mouse brain
(5). This group also showed that the detection of TNF-
,
IL-6, and IFN-
transcripts in the brain was delayed (3).
The low expression of proinflammatory cytokines in the brain is in
accordance with the occasional inflammatory reaction seen in
pathological sections in AIDS patients and even in immunocompetent mice
and might contribute to explain why the infection evolves in the brain
independently of the other compartments (31). The reason for
this compartmentalization could be the rare direct contacts occurring
between the particulate antigens, mostly within the Virchow-Robin
spaces, and the local effector cells (16) such as microglial
macrophages and astrocytes (5, 26), compared to the
ubiquitous contacts that can take place in other organs. A study of
proinflammatory and anti-inflammatory cytokine levels in the
cerebrospinal fluid of a large group of AIDS patients with
cryptococcosis to confirm the in vivo contribution of these cytokines
is under way.
We think that our murine model appropriately mimics the human infection
with the fungemia-meningitis sequence and can be useful for further
investigation of the pathophysiology of cryptococcosis, the unique
behavior of the brain, and new therapeutic approaches. Other in vivo
studies are needed to better explain the mutual influence of C. neoformans and human immunodeficiency virus on cytokine production.
 |
ACKNOWLEDGMENTS |
Olivier Lortholary is the recipient of fellowships from the
Assistance-Publique-Hôpitaux de Paris and Sidaction and of an ASM
travel grant for this work. This work was supported in part by a grant
from the Pasteur Institute (Contrat Interne de Recherche Clinique to
Françoise Dromer).
We thank the members of the French Cryptococcosis Study Group for
enrolling patients in the clinical study and collecting biological
samples. We thank Marlène Nicolas for her help in animal studies,
Karine Sitbon and Amaury de Gouvello for monitoring the clinical study,
and Janet Jacobson for reviewing the English text.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité de
Mycologie, Institut Pasteur, 25, rue du Dr.-Roux, 75724 Paris Cedex 15, France. Phone: 33 1 40 61 33 89. Fax: 33 1 45 68 84 20. E-mail:
dromer{at}pasteur.fr.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Aguirre, K.,
E. A. Havell,
G. W. Gibson, and L. J. Johnson.
1995.
Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice.
Infect. Immun.
63:1725-1731[Abstract].
|
| 2.
|
Amiot, F.,
C. Fitting,
K. J. Tracey,
J. M. Cavaillon, and F. Dautry.
1997.
Lipopolysaccharide-induced cytokine cascade and lethality in LT /TNF -deficient mice.
Mol. Med.
3:864-875[Medline].
|
| 3.
|
Barluzzi, R.,
R. Mazzolla,
A. Brozzetti,
M. Puliti,
G. Mariucci,
P. Mosci,
F. Bistoni, and E. Blasi.
1997.
A low virulent strain of Candida albicans enhances brain anticryptococcal defenses: characterization of the local immune reaction by RT-PCR and histochemical analysis.
J. Neuroimmunol.
79:37-48[Medline].
|
| 4.
|
Bennett, J. E., and H. F. Hasenclever.
1965.
Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection.
J. Immunol.
94:916-920.
|
| 5.
|
Blasi, E.,
R. Barluzzi,
R. Mazzolla,
L. Pitzurra,
M. Puliti,
S. Saleppico, and F. Bistoni.
1995.
Biomolecular events involved in anticryptococcal resistance in the brain.
Infect. Immun.
63:1218-1222[Abstract].
|
| 6.
|
Casadevall, A., and J. R. Perfect.
1998.
Cryptococcus neoformans.
American Society for Microbiology, Washington, D.C.
|
| 7.
|
Chaka, W.,
A. F. M. Verheul, and A. I. M. Hoepelman.
1997.
Influence of different conditions on kinetics of tumor necrosis factor alpha release by peripheral blood mononuclear cells after stimulation with Cryptococcus neoformans: a possible explanation for different results.
Clin. Diagn. Lab. Med.
4:792-794.
|
| 8.
|
Chaka, W.,
A. F. M. Verheul,
V. V. Vaishnav,
R. Cherniak,
J. Scharringa,
J. Verhoef,
H. Snippe, and I. M. Hopelman.
1997.
Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells.
Infect. Immun.
65:272-278[Abstract].
|
| 9.
|
Chensue, S. W.,
P. D. Terebuh,
D. G. Remick,
W. E. Scales, and S. L. Kunkel.
1991.
In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects.
Am. J. Pathol.
138:395-402[Abstract].
|
| 10.
|
Cross, C. E., and G. J. Bancroft.
1995.
Ingestion of acapsular Cryptococcus neoformans occurs via mannose and -glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form.
Infect. Immun.
63:2604-2611[Abstract].
|
| 11.
|
Decken, K.,
G. Köhler,
K. Palmer-Lehmann,
A. Wunderlin,
F. Mattner,
J. Magram,
M. K. Gately, and G. Alber.
1998.
Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans.
Infect. Immun.
66:4994-5000[Abstract/Free Full Text].
|
| 12.
|
Delfino, D.,
L. Cianci,
E. Lupis,
A. Celeste,
M. L. Petrelli,
F. Curro,
V. Cusumano, and G. Teti.
1997.
Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components.
Infect. Immun.
65:2454-2456[Abstract].
|
| 13.
|
Delfino, D.,
L. Cianci,
M. Migliardo,
G. Mancuso,
V. Cusumano,
C. Corradini, and G. Teti.
1996.
Tumor necrosis factor-inducing activities of Cryptococcus neoformans components.
Infect. Immun.
64:5199-5204[Abstract].
|
| 14.
|
Diamond, R. D.
1995.
Cryptococcus neoformans, p. 2331-2340.
In
G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
|
| 15.
|
Dromer, F., and J. Charreire.
1991.
Improved amphotericin B (AMB) activity by a monoclonal anti-Cryptococcus neoformans antibody.
J. Infect. Dis.
163:1114-1120[Medline].
|
| 16.
|
Fabry, Z.,
C. S. Raine, and M. N. Hart.
1994.
Nervous tissue as an immune compartment: the dialect of the immune response in the CNS.
Immunol. Today
15:218-224[Medline].
|
| 17.
|
Havell, E. A., and P. B. Sehgal.
1991.
Tumor necrosis factor-independent IL-6 production during murine listeriosis.
J. Immunol.
146:756-761[Abstract].
|
| 18.
|
Hoag, K. A.,
M. F. Lipscomb,
A. A. Izzo, and N. E. Street.
1997.
Il-12 and IFN- are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice.
Am. J. Respir. Cell Mol. Biol.
17:733-739[Abstract/Free Full Text].
|
| 19.
|
Huffnagle, G. B.
1996.
Role of cytokines in T-cell immunity to a pulmonary Cryptococcus neoformans infection.
Biol. Signals
5:215-222[Medline].
|
| 20.
|
Huffnagle, G. B.,
G. H. Chen,
J. L. Curtis,
R. A. McDonald,
R. M. Strieter, and G. B. Toews.
1995.
Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans.
J. Immunol.
155:3507-3516[Abstract].
|
| 21.
|
Huffnagle, G. B.,
G. B. Toews,
M. D. Burdick,
M. B. Boyd,
K. S. McAllister,
R. A. McDonald,
S. L. Kunkel, and R. M. Strieter.
1996.
Afferent phase production of TNF- is required for the development of protective T cell immunity to Cryptococcus neoformans.
J. Immunol.
157:4529-4536[Abstract].
|
| 22.
|
Joly, V.,
L. Saint-Julien,
C. Carbon, and P. Yeni.
1994.
In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis.
J. Infect. Dis.
170:1331-1334[Medline].
|
| 23.
|
Kawakami, K.,
X. Qifeng,
M. Tohyama,
M. H. Qureshi, and A. Saito.
1996.
Contribution of tumour necrosis factor-alpha (TNF- ) in host defence mechanism against Cryptococcus neoformans.
Clin. Exp. Immunol.
106:468-474[Medline].
|
| 24.
|
Kawakami, K.,
M. Tohyama,
X. Qifeng, and A. Saito.
1997.
Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12.
Infect. Immun.
65:1307-1312[Abstract].
|
| 25.
|
Kawakami, K.,
M. Tohyama,
Q. Sie, and A. Saito.
1996.
IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans.
Clin. Exp. Immunol.
104:208-214[Medline].
|
| 26.
|
Lee, S. C.,
D. W. Dickson,
C. F. Brosnan, and A. Casadevall.
1994.
Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism.
J. Exp. Med.
180:365-369[Abstract/Free Full Text].
|
| 27.
|
Lee, S. C.,
D. W. Dickson, and A. Casadevall.
1996.
Pathology of cryptococcal meningoencephalitis. Analysis of 27 patients with pathogenetic implications.
Hum. Pathol.
27:839-847[Medline].
|
| 28.
|
Levitz, S. M.,
A. Tabuni,
H. Kornfeld,
C. C. Reardon, and D. T. Golenbock.
1994.
Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans.
Infect. Immun.
62:1975-1981[Abstract/Free Full Text].
|
| 29.
|
Levitz, S. M.,
A. Tabuni,
S. Nong, and D. T. Golenbock.
1996.
Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide.
Infect. Immun.
64:945-951[Abstract].
|
| 30.
|
Li, R. K., and T. G. Mitchell.
1997.
Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum.
J. Med. Vet. Mycol.
35:327-334[Medline].
|
| 30a.
|
Lortholary, O.,
L. Improvisi,
N. Rayhane,
M. Nichols,
C. Fitting,
B. DuPont,
J. M. Cavaillon, and F. Dromer.
1998.
Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstr. J-055.
American Society for Microbiology, Washington, D.C.
|
| 31.
|
Lortholary, O.,
L. Improvisi,
M. Nicolas,
F. Provost,
B. Dupont, and F. Dromer.
1999.
Fungemia during murine cryptococcosis sheds some light on pathophysiology.
Med. Mycol.
37:169-174.
[Medline] |
| 32.
|
Mitchell, T. G., and J. R. Perfect.
1995.
Cryptococcosis in the era of AIDS 100 years after the discovery of Cryptococcus neoformans.
Clin. Microbiol. Rev.
8:515-548[Abstract].
|
| 33.
|
Mosmann, T. R., and S. Sad.
1996.
The expanding universe of T-cell subsets: Th1, Th2 and more.
Immunol. Today
17:138-146[Medline].
|
| 34.
|
Munoz, C.,
B. Misset,
C. Fitting,
J. P. Blériot,
J. Carlet, and J. M. Cavaillon.
1991.
Dissociation between plasma and monocyte-associated cytokines during sepsis.
Eur. J. Immunol.
21:2177-2184[Medline].
|
| 35.
|
Murphy, J. W.
1989.
Immunoregulation in cryptococcosis, p. 319-345.
In
E. Kurstak (ed.), Immunology of fungal diseases. Marcel Dekker, Inc., New York, N.Y.
|
| 36.
| Rayhane, N., O. Lortholary, C. Fitting, J. Callebert, M. Huerre, F. Dromer, and J. M. Cavaillon. Enhanced sensitivity
of tumor necrosis factor/lymphotoxin- deficient mice to
Cryptococcus neoformans infection despite increased levels
of nitrite/nitrate, gamma-interferon and interleukin 12. J. Infect. Dis., in press.
|
| 37.
|
Retini, C.,
A. Vecchiarelli,
C. Monari,
C. Tascini,
F. Bistoni, and T. R. Kozel.
1996.
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils.
Infect. Immun.
64:2897-2903[Abstract].
|
| 38.
|
Vecchiarelli, A.,
C. Retini,
C. Monari,
C. Tascini,
F. Bistoni, and T. R. Kozel.
1996.
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.
Infect. Immun.
64:2846-2849[Abstract].
|
| 39.
|
Vecchiarelli, A.,
C. Retini,
D. Pietrella,
C. Monari,
C. Tascini,
T. Beccari, and T. R. Kozel.
1995.
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 secretion from human monocytes.
Infect. Immun.
63:2919-2923[Abstract].
|
| 40.
|
Wang, P.,
P. Wu,
M. I. Siegel,
R. W. Egan, and M. M. Billah.
1994.
IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells.
J. Immunol.
153:811-816[Abstract].
|
| 41.
|
Yuan, R.,
A. Casadevall,
J. Oh, and M. D. Scharff.
1997.
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.
Proc. Natl. Acad. Sci. USA
94:2483-2488[Abstract/Free Full Text].
|
Infection and Immunity, December 1999, p. 6314-6320, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Datta, K., Lees, A., Pirofski, L.-a.
(2008). Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan. CVI
15: 1176-1187
[Abstract]
[Full Text]
-
Charlier, C., Chretien, F., Baudrimont, M., Mordelet, E., Lortholary, O., Dromer, F.
(2005). Capsule Structure Changes Associated with Cryptococcus neoformans Crossing of the Blood-Brain Barrier. Am. J. Pathol.
166: 421-432
[Abstract]
[Full Text]
-
Garcia-Hermoso, D., Dromer, F., Janbon, G.
(2004). Cryptococcus neoformans Capsule Structure Evolution In Vitro and during Murine Infection. Infect. Immun.
72: 3359-3365
[Abstract]
[Full Text]
-
Maffei, C. M. L., Mirels, L. F., Sobel, R. A., Clemons, K. V., Stevens, D. A.
(2004). Cytokine and Inducible Nitric Oxide Synthase mRNA Expression during Experimental Murine Cryptococcal Meningoencephalitis. Infect. Immun.
72: 2338-2349
[Abstract]
[Full Text]
-
Beenhouwer, D. O., Shapiro, S., Feldmesser, M., Casadevall, A., Scharff, M. D.
(2001). Both Th1 and Th2 Cytokines Affect the Ability of Monoclonal Antibodies To Protect Mice against Cryptococcus neoformans. Infect. Immun.
69: 6445-6455
[Abstract]
[Full Text]
-
Neuville, S., Lortholary, O., Dromer, F.
(2000). Do Kinetics of the Humoral Response to Cryptococcus neoformans Proteins during Murine Cryptococcosis Reflect Outcome?. Infect. Immun.
68: 3724-3726
[Abstract]
[Full Text]
-
Rayhane, N., Fitting, C., Lortholary, O., Dromer, F., Cavaillon, J.-M.
(2000). Administration of Endotoxin Associated with Lipopolysaccharide Tolerance Protects Mice against Fungal Infection. Infect. Immun.
68: 3748-3753
[Abstract]
[Full Text]